Frazier Life Sciences Management L.P. Acquires 172,180 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Frazier Life Sciences Management L.P. raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 19.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,044,154 shares of the biopharmaceutical company's stock after buying an additional 172,180 shares during the period. Agios Pharmaceuticals comprises about 1.9% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 16th biggest holding. Frazier Life Sciences Management L.P. owned 1.83% of Agios Pharmaceuticals worth $46,392,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after buying an additional 363 shares during the period. CWM LLC boosted its stake in shares of Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 1,836 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at $146,000.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,542 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Trading Down 5.4 %

Agios Pharmaceuticals stock traded down $2.62 on Tuesday, reaching $46.02. 2,313,335 shares of the stock were exchanged, compared to its average volume of 709,620. The stock has a market cap of $2.62 billion, a PE ratio of 4.05 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a twelve month low of $20.96 and a twelve month high of $62.58. The firm has a fifty day moving average price of $50.09 and a two-hundred day moving average price of $46.68.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Raymond James reaffirmed an "outperform" rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $60.00 to $56.00 in a research note on Friday, September 27th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $56.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.